Skip to main content
Supriya Lifescience Limited logo

Supriya Lifescience Limited — Investor Relations & Filings

Ticker · SUPRIYA ISIN · INE07RO01027 LEI · 894500RBVJX1EOJP0Y02 BSE.NS Manufacturing
Open in API
Filings indexed 486 across all filing types
Latest filing 2026-06-09 Regulatory Filings
Country IN India
Listing BSE.NS SUPRIYA

About Supriya Lifescience Limited

https://www.supriyalifescience.com

Supriya Lifescience Limited is a research-driven manufacturer of Active Pharmaceutical Ingredients (APIs) with a focus on diverse therapeutic segments. The company specializes in the production of antihistamines, anti-allergics, vitamins, anesthetics, and anti-asthmatics. Its core product portfolio includes Chlorpheniramine Maleate, Ketamine Hydrochloride, and Salbutamol Sulphate, maintaining a significant global market share in these niche categories. Operating with a strong emphasis on backward integration, the firm ensures supply chain reliability and cost efficiency. The manufacturing infrastructure is compliant with international regulatory standards, including approvals from the USFDA, EDQM, and PMDA. Supriya Lifescience serves a broad international clientele across more than 100 countries, catering to both regulated and semi-regulated markets through its advanced R&D capabilities and commitment to quality excellence.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 89% confidence The document is a formal SEBI Listing Obligations disclosure to the stock exchanges providing the schedule of analyst/institutional investor meetings and noting that an investor presentation has been uploaded. It does not itself contain financial results, a full presentation, or executive certification, but is a regulatory announcement of an upcoming investor event. Therefore, it fits the general Regulatory Filings category.
2026-06-09 English
Intimation of Investor/Analyst call is enclosed.
Regulatory Filings Classification · 90% confidence The document is a stock exchange disclosure under SEBI Listing Regulations informing of scheduled analyst/institutional investor meetings and noting that an investor presentation has been uploaded. It does not contain substantive financial data or the presentation itself, nor is it a formal report; it is a regulatory announcement. This falls under the fallback category for miscellaneous regulatory filings.
2026-06-09 English
Earnings Call Transcript is enclosed herewith.
Call Transcript Classification · 95% confidence The document is the full text transcript of Supriya Lifescience’s Q4 FY26 earnings conference call, including opening remarks, management discussion, and Q&A. This matches the definition of a Call Transcript.
2026-06-02 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document consists primarily of the full text transcript of the Supriya Lifescience Q4 FY26 earnings conference call, including moderator instructions, management commentary, financial highlights, and a Q&A session. It is not an earnings release summary or investor presentation, but a verbatim earnings call transcript. This matches the definition of a Call Transcript (CT).
2026-06-02 English
Enclosed herewith is the Annual Secretarial Compliance Report
Regulatory Filings Classification · 85% confidence The document is an Annual Secretarial Compliance Report prepared under SEBI LODR Regulation 24A for the year ended March 31, 2026. It is a compliance certification by the Company Secretary, not a financial report (10-K/IR) or management discussion, nor is it an AGM or earnings announcement. It is a regulatory compliance filing and does not fit specialized categories such as audit report (financial audit), board changes, dividends, etc. Under our taxonomy, general compliance certificates and regulatory submissions fall under Regulatory Filings (RNS).
2026-05-30 English
Audio Recording and Outcome of Earnings Call is enclosed herewith.
Report Publication Announcement Classification · 75% confidence The document is a short stock exchange letter notifying that the audio recording of the company’s earnings call (for quarter and year ended March 31, 2026) is now available on the company website. It does not contain any financial data or call transcript itself, but merely announces the publication of the audio recording. This fits the definition of a Report Publication Announcement (RPA).
2026-05-28 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.